Cargando…
Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma
CARM1 is an arginine methyltransferase with diverse histone and non-histone substrates implicated in the regulation of cellular processes including transcriptional co-activation and RNA processing. CARM1 overexpression has been reported in multiple cancer types and has been shown to modulate oncogen...
Autores principales: | Drew, Allison E., Moradei, Oscar, Jacques, Suzanne L., Rioux, Nathalie, Boriack-Sjodin, Ann P., Allain, Christina, Scott, Margaret Porter, Jin, Lei, Raimondi, Alejandra, Handler, Jessica L., Ott, Heidi M., Kruger, Ryan G., McCabe, Michael T., Sneeringer, Christopher, Riera, Thomas, Shapiro, Gideon, Waters, Nigel J., Mitchell, Lorna H., Duncan, Kenneth W., Moyer, Mikel P., Copeland, Robert A., Smith, Jesse, Chesworth, Richard, Ribich, Scott A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5740082/ https://www.ncbi.nlm.nih.gov/pubmed/29269946 http://dx.doi.org/10.1038/s41598-017-18446-z |
Ejemplares similares
-
Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation
por: Thomenius, Michael J., et al.
Publicado: (2018) -
Identification of a peptide inhibitor for the histone methyltransferase WHSC1
por: Morrison, Michael J., et al.
Publicado: (2018) -
EPZ011989, A Potent, Orally-Available EZH2 Inhibitor
with Robust in Vivo Activity
por: Campbell, John E., et al.
Publicado: (2015) -
Re: CaRMS at 50
por: MacFarlane, Malcolm
Publicado: (2020) -
The arginine methyltransferase Carm1 is necessary for heart development
por: Jamet, Sophie, et al.
Publicado: (2022)